<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To validate established cutoff levels of thymidylate synthase (TS) and excision repair cross-complementing (ERCC-1) intratumoral <z:chebi fb="2" ids="33699">mRNA</z:chebi> expressions in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> samples from <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (mCRC) patients treated with PTK787/ZK222584 (PTK/ZK) </plain></SENT>
<SENT sid="1" pm="."><plain>From 122 samples of patients with mCRC enrolled in CONFIRM-1 (Colorectal Oral Novel Therapy for the Inhibition of <z:mpath ids='MPATH_177'>Angiogenesis</z:mpath> and Retarding of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">Metastases</z:e>) or CONFIRM-2, <z:chebi fb="2" ids="33699">mRNA</z:chebi> was isolated of microdissected formalin-fixed paraffin-embedded samples and quantitated using TaqMan-based technology </plain></SENT>
<SENT sid="2" pm="."><plain>Existing TS and ERCC-1 cutoff levels were tested for their prognostic value in first-line and second-line therapy </plain></SENT>
<SENT sid="3" pm="."><plain>TS expression was associated with overall survival (OS) in first-line, but not second-line therapy </plain></SENT>
<SENT sid="4" pm="."><plain>ERCC-1 was associated with OS in patients treated with first-line and second-line FOLFOX4 </plain></SENT>
<SENT sid="5" pm="."><plain>In first-line FOLFOX4, combination of high TS and/or high ERCC-1 was associated with shorter OS </plain></SENT>
<SENT sid="6" pm="."><plain>A correlation was observed between ERCC-1 expression and benefit from PTK/ZK+FOLFOX4 treatment </plain></SENT>
<SENT sid="7" pm="."><plain>TS and ERCC-1 expression is associated with clinical outcome in mCRC </plain></SENT>
<SENT sid="8" pm="."><plain>Baseline TS and ERCC-1 levels may allow the selection of patients who benefit from FOLFOX4 chemotherapy </plain></SENT>
</text></document>